Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

White House Says Senior Staff Has Followed Up With McCarthy’s Office After Spending Talks

– Reuters

byHappy Mohamed

February 2, 2023

1 minute read

– Reuters

Recap: Rite Aid Q1 Earnings

By Benzinga Insights

Today, 6:50 AM

Shares of Rite Aid (NYSE:RAD) moved higher by 2.4% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 1050.00% over the past year to $0.38, which beat the estimate of $0.22.

RAD

J&J Is Confident It Will Deliver A Billion COVID-19 Vaccine Doses Next Year, Says Will Give Financial Guidance On Vaccine In Jan. 2022

By Benzinga Newsdesk

Today, 6:50 AM

-Reuters

JNJ

News

VYNE Therapeutics Announces Initiation Of Investigator-Initiated Trial Evaluating AMZEEQ With Oral Isotretinoin In Patients With Moderate To Severe Acne

By Benzinga Newsdesk

Today, 6:50 AM

VYNE Therapeutics Inc. (NASDAQ:VYNE) (“VYNE” or the “Company”) today announced the initiation of an investigator initiated trial (“IIT” or “study”) evaluating the safety

VYNE

Windtree Highlights Late-Breaker Presentation On Phase 2 SEISMiC Study Results Of Istaroxine In Early Cardiogenic Shock At European Society Of Cardiology Heart Failure Conference May 22

By Benzinga Newsdesk

Today, 6:50 AM

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced a late-breaker presentation

WINT

White House Says Senior Staff Has Followed Up With McCarthy’s Office After Spending Talks

Related Posts

Recap: Rite Aid Q1 Earnings

J&J Is Confident It Will Deliver A Billion COVID-19 Vaccine Doses Next Year, Says Will Give Financial Guidance On Vaccine In Jan. 2022

VYNE Therapeutics Announces Initiation Of Investigator-Initiated Trial Evaluating AMZEEQ With Oral Isotretinoin In Patients With Moderate To Severe Acne

Windtree Highlights Late-Breaker Presentation On Phase 2 SEISMiC Study Results Of Istaroxine In Early Cardiogenic Shock At European Society Of Cardiology Heart Failure Conference May 22